Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Jackisch

Showing results (71-80 of 231) with videos related to

Pageof 24
Sort By:
Breast Cancer Research : BCR|April 3, 2008
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastGunter von Minckwitz, Hans-Peter Sinn, Günter Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsiesAnnette Lebeau, Andreas Turzynski, Susanne Braun, et al.
Annals of Surgical Oncology|September 20, 2006
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trialSibylle Loibl, Gunter von Minckwitz, Günther Raab, et al.
Future Oncology (London, England)|May 13, 2026
Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journeyMatteo Lambertini, Christian Jackisch, Olivier Trédan, et al.
Langenbeck'S Archives of Surgery|July 9, 2025
Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplinesLudger Staib, Frank Willeke, Dietmar Stephan, et al.
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Breast (Edinburgh, Scotland)|March 30, 2025
Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European surveyMatteo Lambertini, Christian Jackisch, Olivier Trédan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
Breast (Edinburgh, Scotland)|January 8, 2017
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trialsMattea Reinisch, Jens Huober, Gunter von Minckwitz, et al.
Pageof 24

Showing results (71-80 of 231) with videos related to

Sort By:
Pageof 24
Breast Cancer Research : BCR|April 3, 2008
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastGunter von Minckwitz, Hans-Peter Sinn, Günter Raab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsiesAnnette Lebeau, Andreas Turzynski, Susanne Braun, et al.
Annals of Surgical Oncology|September 20, 2006
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trialSibylle Loibl, Gunter von Minckwitz, Günther Raab, et al.
Future Oncology (London, England)|May 13, 2026
Plain language summary about how patients with HER2 positive breast cancer across Europe feel about their cancer, treatment, and future health and related implications for their treatment journeyMatteo Lambertini, Christian Jackisch, Olivier Trédan, et al.
Langenbeck'S Archives of Surgery|July 9, 2025
Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplinesLudger Staib, Frank Willeke, Dietmar Stephan, et al.
Human Pathology|January 24, 2006
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neuRaihanatou Diallo, Achim Rody, Christian Jackisch, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Breast (Edinburgh, Scotland)|March 30, 2025
Patient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European surveyMatteo Lambertini, Christian Jackisch, Olivier Trédan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
Breast (Edinburgh, Scotland)|January 8, 2017
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trialsMattea Reinisch, Jens Huober, Gunter von Minckwitz, et al.
Pageof 24